Table 3:
IPA-Related Treatment-Emergent Adverse Events with CTCAE Grade ≥3 by System Organ Class
| Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Expansion Cohort | Overall N=37 n (%) |
|
|---|---|---|---|---|---|---|---|
| Dose of Ipafricept (Q3W) System Organ Class/ |
5 mg/kg N=3 n (%) |
10 mg/kg N=4 n (%) |
2 mg/kg N=8 n (%) |
4 mg/kg N=9 n (%) |
6 mg/kg N=6 n (%) |
6 mg/kg N=7 n (%) |
|
| Patients reporting ≥1 IPA related TEAE with CTCAE≥ Grade 3 | 3 (100.0) | 0 | 1(12.5) | 0 | 1(16.7) | 3(42.9) | 8(21.6) |
| Investigations | 3 (100) | 0 | 0 | 0 | 0 | 3(42.9) | 6(16.2) |
| Neutropenia | 3 (100) | 0 | 0 | 0 | 0 | 3(42.9) | 5(13.5) |
| Metabolism and nutrition disorders | 0 | 0 | 1(12.5) | 0 | 0 | 0 | 1(2.7) |
| Hypophosphatemia | 0 | 0 | 1(12.5) | 0 | 0 | 0 | 1(2.7) |
| Gastrointestinal disorders | 0 | 0 | 0 | 0 | 1 (16.7) | 0 | 1(2.7) |
| Diarrhea | 0 | 0 | 0 | 0 | 1 (16.7) | 0 | 1(2.7) |
| Nervous system disorders | 0 | 0 | 0 | 0 | 0 | 1(14.3) | 1(2.7) |
| Neuropathy peripheral | 0 | 0 | 0 | 0 | 0 | 1(14.3) | 1(2.7) |